Beneficial effect of growth hormone on atherogenic risk in children with growth hormone deficiency

• Published in: The Journal of pediatrics Vol. 126; no. 6; pp. 953 - 955
• Main Authors: Kohno, Hitoshi, Ueyama, Nami, Yanai, Shinji, Ukaji, Koutaro, Honda, Sunao
• Format: Journal Article Conference Proceeding
• Language: English
• Published: New York, NY Elsevier Inc 01.06.1995; Elsevier
• Subjects: Adolescent; Arteriosclerosis - prevention & control; Biological and medical sciences; Child; Cholesterol - blood; Cholesterol, HDL - blood; Endocrinopathies; Growth Hormone - deficiency; Growth Hormone - therapeutic use; Humans; Hypothalamus. Hypophysis. Epiphysis (diseases); Male; Medical sciences; Non tumoral diseases. Target tissue resistance. Benign neoplasms; Recombinant Proteins - therapeutic use; Risk Factors; AI; GH; HDLC; TC; Endocrinopathy; Human; Deficiency; STH; Cardiovascular disease; Lipids; Exploration; Male; Cholesterol; Blood; Vascular disease; Assay; Pituitary hormone; Chemotherapy; Treatment; Pituitary diseases; Atherosclerosis; Risk factor; Child
• ISSN: 0022-3476; 1097-6833
• DOI: 10.1016/S0022-3476(95)70220-2

We studied changes in the atherogenic index (total cholesterol ÷ high-density lipoprotein cholesterol) in 12 prepubertal boys with growth hormone (GH) deficiency during 9 months of GH treatment. High-density lipoprotein cholesterol level increased until 5 months without significant changes in total cholesterol level; thus GH therapy may be beneficial in reducing the atherogenic index in boys with GH deficiency. (J PEDIATR 1995;126:953-5)